Showing 2611-2620 of 5956 results for "".
- Refractive Surgery Council Reports Strongest H1 Laser Vision Correction (LVC) Procedure Volume Growth in Nearly a Decadehttps://modernod.com/news/refractive-surgery-council-reports-strongest-h1-laser-vision-correction-lvc-procedure-volume-growth-in-nearly-a-decade/2479384/The Refractive Surgery Council (RSC) reported the strongest first half laser vision correction (LVC) procedure volume growth in nearly a decade. The 82 percent year-over-year growth, fueled by the strong quarter-over-quarter performance, resulted in 231,503 LASIK, SMILE and PRK procedures perform
- EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-receives-preliminary-extension-to-pass-through-payment-status-for-dexycu/2479385/EyePoint Pharmaceuticals announced today that the company expects to receive a 9-month extension on Dexycu’s pass-through payment status, which otherwise would expire on March 31, 2022. On July 19, 2021, CMS released its 2022 draft Hospital Outpatient Prospective
- FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 for the Treatment of Stargardt Diseasehttps://modernod.com/news/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease/2479374/Alkeus Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A developed to treat multiple retinal degenerati
- Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet AMDhttps://modernod.com/news/optheas-opt-302-granted-fda-fast-track-designation-for-wet-amd/2479360/Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with wet age-related macular degeneration (AMD). The FDA’s Fast Track pro
- Horizon Therapeutics Partners With Olympic Gold Medalist Gail Devers to Raise Awareness of Graves’ Disease and Symptoms of Thyroid Eye Disease (TED)https://modernod.com/news/horizon-therapeutics-partners-with-olympic-goldmmedalist-gail-devers-to-raise-awareness-of-graves-disease-and-symptoms-of-thyroid-eye-disease-ted/2479357/For Graves’ Disease Awareness Month in July, Horizon Therapeutics is teaming up with track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Ms. Devers are collaborating wit
- Mikajaki Partners With Segula Technologies to Develop Ophthalmic Diagnosis Devicehttps://modernod.com/news/mikajaki-partners-with-segula-technologies-to-develop-ophthalmic-diagnosis-device/2479353/Swiss startup Mikajaki is teaming up with engineering group Segula Technologies to develop the first operational series of EyeLib, an automated diagnostic station that aims to revolutionize the management of the growing number of patients with vision disorders, according to a company news release
- Contact Lens Institute Unveils Nationwide “See Tomorrow Campaign;” Industry Launch Event Slated for July 22https://modernod.com/news/contact-lens-institute-unveils-nationwide-see-tomorrow-campaign-industry-launch-event-slated-for-july-22/2479347/A new professional and consumer initiative from the Contact Lens Institute (CLI) is poised to reveal insights about how patient psyches surrounding vision, health care and their lives have changed over the course of the pandemic—and the ensuing opportunities for the optometry community. The CLI <
- Oasis TEARS PF PLUS Preservative-Free Lubricant Eye Drops Now Delivered in a Bottlehttps://modernod.com/news/oasis-tears-pf-plus-preservative-free-lubricant-eye-drops-now-delivered-in-a-bottle/2479338/Oasis Medical is launching Oasis TEARS PF PLUS preservative-free lubricant eye drops delivered in a 10mL bottle for multiuse. Lubricant eye drops, which are packaged in traditional multi-use bottles, contain preservatives to prevent microbial growth. Preservative-free lubricant eye drops a
- ASCRS: Insurance Company Policy Delays Sight-Restoring Surgery, Puts Patients in Jeopardyhttps://modernod.com/news/ascrs-insurance-company-policy-delays-sight-restoring-surgery-puts-patients-in-jeopardy/2479334/The decision by Aetna to require preauthorization of all cataract surgery procedures went into effect July 1. In a news release, ASCRS said it is opposed to the preauthorization policy, stating it will create delays i
- PYC Therapeutics Announces Preclinical Results Demonstrating VP-002 Program’s Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophyhttps://modernod.com/news/pyc-therapeutics-announces-comprehensive-preclinical-results-demonstrating-vp-002-programs-potential-as-the-first-disease-modifying-therapy-for-autosomal-dominant-optic-atrophy/2479330/PYC Therapeutics released a summary of preclinical findings supporting the potential of PYC’s VP-002 program as the first disease-modifying therapy for patients suffering from Autosomal Dominant Optic Atrophy (ADOA). PYC’s PPMO technology used in the VP-002 program significantly increases levels